
Editas Medicine, Inc. (NASDAQ:EDIT – Free Report) – Stock analysts at HC Wainwright increased their FY2026 EPS estimates for Editas Medicine in a note issued to investors on Tuesday, November 10th. HC Wainwright analyst M. Kapoor now forecasts that the company will post earnings per share of ($0.61) for the year, up from their previous estimate of ($0.66). The consensus estimate for Editas Medicine’s current full-year earnings is ($0.79) per share. HC Wainwright also issued estimates for Editas Medicine’s Q1 2027 earnings at ($0.21) EPS and Q2 2027 earnings at ($0.22) EPS.
A number of other equities analysts have also recently weighed in on EDIT. Guggenheim raised Editas Medicine from a “neutral” rating to a “buy” rating and set a $5.00 price target for the company in a report on Wednesday, September 23rd. Wall Street Zen raised Editas Medicine from a “sell” rating to a “hold” rating in a report on Saturday, August 8th. Ladenburg Thalmann & Co. Inc. assumed coverage on Editas Medicine in a report on Tuesday, August 18th. They issued a “buy” rating and a $6.00 price objective on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Editas Medicine in a research report on Wednesday, November 4th. Finally, Wells Fargo & Company upgraded Editas Medicine from an “equal weight” rating to an “overweight” rating and boosted their price objective for the company from $4.00 to $6.00 in a research report on Thursday, October 8th. Six equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Editas Medicine presently has a consensus rating of “Moderate Buy” and an average price target of $5.83.
Editas Medicine Stock Performance
NASDAQ:EDIT opened at $2.17 on Thursday. Editas Medicine has a 52 week low of $1.66 and a 52 week high of $3.94. The stock’s 50-day moving average price is $2.63 and its 200-day moving average price is $2.69.
Editas Medicine (NASDAQ:EDIT – Get Free Report) last issued its quarterly earnings data on Monday, November 9th. The company reported ($0.15) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.04. Editas Medicine had a negative net margin of 144.95% and a negative return on equity of 130.43%. The business had revenue of $10.37 million during the quarter, compared to the consensus estimate of $4.46 million.
Hedge Funds Weigh In On Editas Medicine
A number of hedge funds have recently made changes to their positions in EDIT. Marshall Wace LLP raised its holdings in shares of Editas Medicine by 48.5% during the third quarter. Marshall Wace LLP now owns 3,024,503 shares of the company’s stock valued at $7,773,000 after acquiring an additional 987,216 shares during the last quarter. Empowered Funds LLC acquired a new stake in shares of Editas Medicine in the third quarter worth approximately $318,000. HighVista Strategies LLC acquired a new stake in shares of Editas Medicine in the third quarter worth approximately $2,845,000. State Street Corp increased its position in shares of Editas Medicine by 60.6% during the third quarter. State Street Corp now owns 7,038,580 shares of the company’s stock worth $18,089,000 after purchasing an additional 2,654,974 shares in the last quarter. Finally, Private Advisor Group LLC purchased a new stake in shares of Editas Medicine during the third quarter worth approximately $31,000. Institutional investors and hedge funds own 71.90% of the company’s stock.
Insider Buying and Selling at Editas Medicine
In related news, CEO Gilmore O’neill sold 21,164 shares of the firm’s stock in a transaction dated Wednesday, November 11th. The shares were sold at an average price of $2.42, for a total value of $51,216.88. Following the transaction, the chief executive officer directly owned 265,592 shares of the company’s stock, valued at approximately $642,732.64. This trade represents a 7.38% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last three months, insiders have sold 35,264 shares of company stock worth $89,236. 3.10% of the stock is owned by corporate insiders.
Editas Medicine Company Profile
Editas Medicine, Inc. is a biotechnology company developing genome-editing medicines for people with serious diseases. Its research uses CRISPR-based technologies, including CRISPR-Cas9 and Cas12a, to make targeted changes to DNA. Founded in 2013 and based in Cambridge, Massachusetts, the company conducts research and clinical development of potential treatments for genetic disorders. Its work has included approaches designed to edit genes in a patient’s cells, either outside the body or directly within the body.
Recommended Stories
- Five stocks we like better than Editas Medicine
- Nu Holdings Earnings Show a Compounder Priced Like a Brazil Bet
- Game On: The Hidden Value in Take-Two’s Stock
- LightPath Technologies’ Record Backlog Highlights a Bigger Defense Opportunity
- A 10-Stock Strategy That Balances AI Growth With Cash Flow
Receive News & Ratings for Editas Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Editas Medicine and related companies with MarketBeat.com's FREE daily email newsletter.
